Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $13.78 USD
Change Today -0.43 / -3.03%
Volume 14.8K
As of 8:10 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

astellas pharma inc-unsp adr (ALPMY) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/24/15 - $16.99
52 Week Low
09/4/15 - $13.75
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

astellas pharma inc-unsp adr (ALPMY) Related Businessweek News

View More BusinessWeek News

astellas pharma inc-unsp adr (ALPMY) Details

Astellas Pharma Inc. manufactures, markets, and imports/exports pharmaceutical products worldwide. The company focuses on the therapeutic areas of urology, immunology and infectious diseases, oncology, neuroscience, and diabetes mellitus complications and kidney diseases. The company offers immunosuppressants, including Prograf, and Advagraf/ Graceptor/ ASTAGRAF XL; Vesicare and Betanis/Myrbetriq/BETMIGA for overactive bladder treatment; and Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia. It also provides Funguard/MYCAMINE, a candin antifungal agent; Protopic for atopic dermatitis; Eligard, XTANDI, and Gonax for prostate cancer treatment; Micardis, including Micombi and Micamlo BP for hypertension; Celecox, an anti-inflammatory agent; Symbicort for adult bronchial asthma and chronic obstructive pulmonary disease; Geninax for oral quinolone antibiotic; Bonoteo for osteoporosis; Cimzia for the treatment of adult patients with rheumatoid arthritis; and Suglat for type two diabetes treatments. In addition, the company offers Lipitor products for the treatment of hypercholesterolemia; Gaster for peptic ulcers and gastritis; Myslee for insomnia; Seroquel for schizophrenia; Regnite for restless legs syndrome; Kiklin for hyperphatemia treatments, as well as Lexiscan and Adenoscan, which are pharmacologic stress agents; and Tarceva for the treatment of lung and pancreatic cancers. Further, it provides Acofide for functional dyspepsia; Bisono Tape, a transdermal hypertension medication; diarrhea-predominant OD tablets; and dificlir for clostridium difficile infections. It has a strategic alliance with Amgen Inc. and ClearPath Development Company; and collaborative agreements with Immuno-Biological Laboratories Co., Ltd., Cytokinetics, Inc., Mitokyne, Inc., QIAGEN N.V., Dana-Farber Cancer Institute, and Ventana Medical Systems, Inc. The company was founded in 1923 and is headquartered in Tokyo, Japan.

17,113 Employees
Last Reported Date: 06/17/15
Founded in 1923

astellas pharma inc-unsp adr (ALPMY) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥182.0M
Chief Administrative Officer, Chief Complianc...
Total Annual Compensation: ¥88.0M
Compensation as of Fiscal Year 2015.

astellas pharma inc-unsp adr (ALPMY) Key Developments

Astellas Pharma, Inc., Q1 2016 Earnings Call, Jul 31, 2015

Astellas Pharma, Inc., Q1 2016 Earnings Call, Jul 31, 2015

Astellas Pharma, Inc. Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2015; Provides Earnings Guidance on Core and Full Basis for the Fiscal Year 2015

Astellas Pharma, Inc. announced consolidated earnings results for the first quarter ended June 30, 2015. For the period, the company reported sales of JPY 343,659 million against JPY 295,157 million a year ago. Operating profit was JPY 61,911 million against JPY 50,565 million a year ago. Profit before tax was JPY 67,664 million against JPY 50,278 million a year ago. Profit attributable to owners of the parent was JPY 44,622 million against JPY 35,861 million a year ago. Earnings per diluted share were JPY 20.35 against JPY 16.13 a year ago. Net cash flows from operating activities was JPY 29,642 million against JPY 60,653 million a year ago. Purchases of property, plant and equipment was JPY 9,236 million against JPY 5,348 million a year ago. Purchase of intangible assets was JPY 5,924 million against JPY 11,519 million a year ago. Core operating profit was JPY 67,820 million against JPY 65,976 million a year ago. Core profit for the period was JPY 46,409 million against JPY 45,031 million a year ago. For the fiscal year 2015, on core basis, sales are expected to be JPY 1,362,000 million, Core operating profit is expected to be JPY 238,000 million, Core profit for the year is expected to be JPY 170,000 million and basic core earnings per share is expected to be JPY 78.08. For the fiscal year 2015, on full basis, sales are expected to be JPY 1,362,000 million, operating profit is expected to be JPY 238,000 million, profit before tax is expected to be JPY 239,000 million, profit for the year is expected to be JPY 170,000 million and basic earnings per share is expected to be JPY 78.08.

Astellas Pharma, Inc. Provides Dividend Guidance for the Full Year of 2015

Astellas Pharma, Inc. provided dividend guidance for the full year of 2015. For the year, the company expects to pay JPY 32 per share against JPY 30 per share paid a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALPMY:US $13.78 USD -0.43

ALPMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $134.32 USD -2.21
Boston Scientific Corp $16.24 USD -0.29
CSL Ltd A$90.18 AUD +0.16
Mylan NV $48.05 USD +0.63
Solvay SA €102.70 EUR -1.95
View Industry Companies

Industry Analysis


Industry Average

Valuation ALPMY Industry Range
Price/Earnings 26.4x
Price/Sales 2.9x
Price/Book 2.8x
Price/Cash Flow 20.8x
TEV/Sales 2.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTELLAS PHARMA INC-UNSP ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at